Previous Article | Next Article 
Journal of Clinical Microbiology, October 2001, p. 3583-3585, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3583-3585.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Rapid Identification and Antibiotic Susceptibility Testing
of Salmonella enterica Serovar Typhi Isolated from
Blood: Implications for Therapy
Samir K.
Saha,1,2,*
Gary L.
Darmstadt,3,4
Abdullah H.
Baqui,3
M.
Hanif,1,2
M.
Ruhulamin,1,2
Mathuram
Santosham,3
T.
Nagatake,5 and
Robert
E.
Black3
Department of Microbiology, Institute of Child Health,
Dhaka Shishu Hospital,1 and Popular
Diagnostic Centre,2 Dhaka, Bangladesh;
Department of International Health, School of Hygiene and
Public Health, The Johns Hopkins Medical Institutions, Baltimore,
Maryland3; Office of Health, Save the
Children Federation, Washington, D.C.4; and
Department of Internal Medicine, Institute of Tropical
Medicine, Nagasaki University, Nagasaki, Japan5
Received 25 April 2001/Returned for modification 29 May
2001/Accepted 11 July 2001
 |
ABSTRACT |
The turnaround time (TAT) for Salmonella
enterica serovar Typhi identification and reporting
of the antibiotic susceptibility profile was determined for 391 cases of typhoid fever, using the lysis direct plating or lysis
centrifugation method of blood culture along with rapid
antimicrobial susceptibility testing. The TAT was more rapid (TAT for
90% of the patients [TAT90] = 30 h;
TAT100
67 h) than was possible with
conventional methodologies and was equivalent to that reported
previously using more advanced, costly technologies that are largely
unavailable in developing countries. Antibiotic susceptibility
profiles, determined by the rapid antimicrobial susceptibility testing
method, of randomly selected 60 S. enterica serovar
Typhi isolates were identical to those determined by overnight
conventional testing. Preliminary assessment of the impact of the
reduced TAT on physician practices revealed that initial
empirical therapy was prescribed at the time of presentation in most
cases (87 of 108 [81%]) despite awareness that the final report
would be available on the following day. Patients treated
empirically with first-line antibiotics and shown subsequently to be
infected with a multidrug-resistant strain benefited most (8 cases), since therapy was changed appropriately on the following day.
In an additional 21 cases, therapy with an appropriate antibiotic was
initiated after culture results were available. Thus, in approximately
one-fourth (29 of 108 [27%]) of the cases, a change in management to
an agent active for treatment of the isolate was made after receipt of
the test results. However, in no case was therapy changed from a
second-line to a first-line agent, even if the isolate was reported
on the day after presentation to be sensitive to first-line therapy (33 cases). Ways in which to utilize rapid-TAT result reporting in order to
positively influence physicians' prescribing in Bangladesh are the
subject of ongoing research.
 |
INTRODUCTION |
Despite the increased
availability of innovative molecular technologies for detecting
and reporting microbial pathogens, most clinicians still regard the
antimicrobial susceptibility report as the most important test result
generated by the clinical microbiology laboratory
(3). Several studies have shown that antimicrobial susceptibility results, however, generally have not significantly influenced physicians' choices of appropriate antimicrobial therapies (5). The long turnaround time (TAT) required to generate
the report using conventional methods and poor communication between the laboratory and physicians (3) likely contribute to the lack of impact of the antibiotic susceptibility report on clinical practice. Rapid identification of the etiologic agent of infection and
its antimicrobial susceptibility profile by using advanced laboratory
technology and instant dissemination of the information through
hospital- and laboratory-based computer network systems could
rationalize antimicrobial therapy. These methods, however, are
largely unavailable in the developing world. Thus, the development of
low-technology, low-cost methods for reducing TAT and improving flow of
information to physicians is needed to effectively treat infections
while minimizing unwarranted use of broad-spectrum antibiotics in the
developing world.
The goals of this study were (i) to evaluate the TAT of the lysis
direct plating-lysis centrifugation (LDP-LC) method of blood culture,
along with rapid antimicrobial susceptibility testing (RAST), for
processing isolates of Salmonella enterica serovar Typhi and
(ii) to perform a preliminary assessment of the impact of the rapid TAT
of the LDP-LC-RAST method on the therapeutic management of typhoid
fever by clinicians.
 |
MATERIALS AND METHODS |
Patients.
Patients were referred by community practitioners,
clinics, and hospitals throughout Dhaka City, Bangladesh, to the
Popular Diagnostic Centre, a private laboratory and clinical diagnostic facility, for evaluation of possible serious bacterial infection from
August 1998 to November 1999 (9). Isolates of S. enterica serovar Typhi from these patients were chosen for further study.
Laboratory procedure.
Blood cultures were performed by the
LDP-LC method (10) with 2 ml of blood from patients up
to 12 years of age and 5 ml of blood from patients in older age groups.
Specimens were cultured on sheep blood and MacConkey agar plates, and
the number of bacteria per milliliter of blood was determined by plate
counting. Suspected colonies of S. enterica serovar Typhi
were immediately identified by agglutination with specific antisera
(Murex, Dartford, United Kingdom), and RAST was performed as described
by Granato (3). In brief, instead of conventional
overnight incubation of susceptibility test plates, the readings for
antibiotic sensitivity results were obtained after 8 h of
incubation (Table 1). If agglutination testing was negative or doubtful, identification was performed by
standard biochemical tests and repeat agglutination testing 24 h
later (9). In these cases, however, the growth was
reported generically as gram-negative bacilli, and RAST results were
provided with a note that precise identification of the isolate would
be confirmed the following day. Antibiograms of the strains were interpreted according to National Committee for Clinical Laboratory Standards recommendations (7). Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used
for quality control. The antibiograms of randomly selected
multidrug-resistant (MDR) (n = 40) and
multidrug-susceptible (n = 20) strains of S. enterica serovar Typhi were obtained by both RAST and conventional
antibiotic sensitivity testing methods to determine their concordance
(7).
Physicians' practice.
Several seminars and meetings were
organized (i) to inform referring physicians about the rapid reporting
system and the availability of isolate identification and antibiogram
results within 24 h of obtaining blood cultures and (ii) to
encourage them to refrain, when feasible, from prescribing empirical
antibiotic therapy until after receiving the antibiogram; to utilize
first-line therapy when prescribing antibiotics empirically; and to
make appropriate and prompt adjustments in therapy once the antibiogram
was available. Impact of rapid reporting on management of the S. enterica serovar Typhi-infected patients of three of the
physicians with the busiest practices was determined retrospectively by
either reviewing the physician's prescriptions or contacting them
personally to determine prescribing patterns.
 |
RESULTS |
A total of 4,650 blood cultures were received in the 15-month
study period. Of these cultures, 538 (11.6%) produced significant growth, and 72.7% (391 of the 538) of this group of cultures were determined to be S. enterica serovar Typhi, as reported
previously (9). More than 90% (342 of 391) of the typhoid
cases were identified by the LDP-LC method within 12 to 24 h of
inoculation (by 10 a.m. on the second day [Table 1]), and RAST
results were available within the subsequent 8 h. The
TAT100 value (i.e., the TAT for all [100%] of
the patients) was
67 h (Fig. 1). The
susceptibilities of 60 S. enterica serovar Typhi strains to
ampicillin, cotrimoxazole, chloramphenicol, ciprofloxacin, and
ceftriaxone were found to be identical by the RAST method to those
obtained by overnight conventional testing (data not shown).
Follow-up of treatment by physicians revealed that empirical therapy
was started in 81% of the cases evaluated (87 of 108) before the
culture sensitivity report was available (Table
2). In approximately half (47 of 87 [54%]) of these cases, the empirical choice was an appropriate
first-line antibiotic (amoxicillin, cotrimoxazole, or chloramphenicol).
In only 17% (8 of 47) of these cases was it necessary to change from a
first-line to a second-line agent (ceftriaxone or ciprofloxacin),
either because the isolate was MDR (n = 3) or because
it displayed isolated resistance to the empirically prescribed
first-line agent (n = 5). Moreover, in 21 cases,
therapy with an appropriate antibiotic was initiated after culture
results were available. Thus, in a total of 27% (29 of 108) of the
cases, a change in management to an agent active for treatment of the
isolate was made after the receipt of test results. On the other hand,
empirical therapy was initiated in 40 cases with a second-line
antibiotic (ciprofloxacin, n = 17; ceftriaxone,
n = 23); 33 (83%) of these isolates, however,
were sensitive to the first-line antibiotic. In none of these cases was
the prescribed antibiotic changed to a first-line antibiotic after the
susceptibility report was received. However, there was no difference in
final outcome since all patients were cured without any complications.
 |
DISCUSSION |
Typhoid fever is endemic in Bangladesh, where there is a high
incidence in children (9). The emergence of MDR
S. enterica serovar Typhi isolates in the early
1990s, particularly from the Indian subcontinent, prompted the
suggestion that ciprofloxacin or ceftriaxone should be the drug
of choice for empirical treatment of typhoid fever (4, 8,
11). Initially, reduced use of amoxicillin, cotrimoxazole, or
chloramphenicol was associated with a decreased prevalence of MDR
strains (12), but more recently, continued dependence on
ciprofloxacin or ceftriaxone for the empirical treatment of typhoid
fever in Bangladesh and elsewhere has led to the emergence of
resistance of S. enterica serovar Typhi to these drugs
(6, 13).
In this context of changing the dynamics of resistance to antibiotics,
it is imperative for optimal patient care that accurate information on
S. enterica serovar Typhi isolation and its antibiotic susceptibility pattern be available to the clinician as rapidly as
possible. A recent study demonstrated that faster reporting with
advanced technology (e.g., the Vitek system for isolate identification and antibiotic susceptibility testing or automated, computerized laboratory information systems), along with changes in the workflow, could save hospital costs and improve patient care (1).
The advanced equipment needed for such rapid reporting is expensive, however, and incurs a high recurring cost. Consequently, these methods
are not yet available in most clinical laboratories in developing
countries. Even in the developed part of the world, the use of these
advanced technologies is feasible only for relatively large
laboratories and hospitals.
We showed here that the TAT for the identification and anitimicrobial
sensitivity testing of S. enterica serovar Typhi can be
substantially reduced to the level of modern technologies by using
rapid but relatively low-cost, low-technology blood culture and
susceptibility testing methods. A TAT90 of
30 h
achieved using these methods was at least as rapid as that of advanced
"state-of-the-art" methodologies (1, 14). On the other
hand, the minimum TAT achievable by conventional broth culture would be
96 h (10, 15). The rapid method described here did
not require any additional equipment or laboratory personal and
produced antibiogram results identical to those obtained by conventional methods.
In Bangladesh, empirical therapy is the rule rather than the exception
(2). In the present study, >80% of cases evaluated were
treated empirically, even though a report was expected within the next
24 h and the referring physicians had received instructions about
the methodology and the benefits of waiting for test results before
initiating therapy. In more than one-fourth of these cases, however,
including patients infected with MDR strains, a change from ineffective
to effective therapy was made after the receipt of test results and the
ultimate outcome was good since the patients recovered without
complications. On the other hand, the availability of results did not
result in a change if therapy was initiated with a relatively expensive
second-line empirical antibiotic, even though the isolate was
susceptible to less-expensive first-line agents.
These data are preliminary and do not include an evaluation of
prescribing patterns for either culture-negative patients or for
typhoid patients before introduction of the rapid-TAT system, both of
which would provide additional important insights into the influence of
rapid TAT on prescribing patterns. Finding ways in which to utilize
reporting of rapid-TAT results to positively influence physician
prescribing in Bangladesh is the subject of ongoing research.
In summary, a reduced TAT for isolate identification and antibiogram
results by using the rapid LDP-LC-RAST method was achieved with equal
precision but without additional costs compared to conventional
methodologies. This approach may improve the quality and cost of
patient care in the developing world, where typhoid fever is endemic,
MDR strains are relatively common, and the availability of advanced
diagnostic laboratory methods is limited.
 |
ACKNOWLEDGMENTS |
The study was partially supported by the Popular Diagnostic
Centre, Dhaka, Bangladesh, and the Bill and Melinda Gates Foundation.
We gratefully acknowledge the technical assistance of Maksuda Islam.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Institute of Child Health, Dhaka Shishu Hospital,
Dhaka-1207, Bangladesh. Phone: 880-2-811-6101. Fax:
880-2-9128308. E-mail: sksaha{at}bangla.net.
 |
REFERENCES |
| 1.
|
Barenfanger, J.,
C. Drake, and G. Kacich.
1999.
Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing.
J. Clin. Microbiol.
37:1415-1418[Abstract/Free Full Text].
|
| 2.
|
Bennish, M.
1987.
The Bangladesh drug policy. The next step: using good drugs "goodly."
Bangladesh J. Child Health
11:63-72.
|
| 3.
|
Granato, P. A.
1993.
The impact of same-day tests versus traditional overnight testing.
Diagn. Microbiol. Infect. Dis.
16:237-243[CrossRef][Medline].
|
| 4.
|
Jesudassan, M. V., and J. T. Jacob.
1990.
Multiresistant Salmonella typhi in India.
Lancet
336:252.
|
| 5.
|
Masten, J. A.
1981.
Rapid reporting of results: impact on patients and physicians and the laboratory, p. 98-102.
In
R. C. Tilton (ed.), Rapid methods in automation and microbiology. American Society for Microbiology, Washington, D.C.
|
| 6.
|
Murdoch, D. A.,
N. Banatvaia,
A. Bone,
B. I. Shoismatulloev,
L. R. Ward, and E. J. Threlfall.
1998.
Epidemic ciprofloxacin-resistant Salmonella typhi in Tajakistan.
Lancet
351:339[CrossRef][Medline].
|
| 7.
|
National Committee for Clinical Laboratory Standards.
1998.
Performance of standards for antimicrobial susceptibility testing: eighth international supplement. NCCLS document, vol. 18, no. 1.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 8.
|
Rowe, B.,
L. R. Ward, and E. J. Threlfall.
1990.
Spread of multiresistant Salmonella typhi.
Lancet
336:1065[CrossRef][Medline].
|
| 9.
|
Saha, S. K.,
A. H. Baqui,
M. Hanif, et al.
2001.
Typhoid fever in Bangladesh: implications for vaccination policy.
Pediatr. Infect. Dis. J.
20:521-524[Medline].
|
| 10.
|
Saha, S. K.,
W. A. Khan, and S. Saha.
1992.
Blood cultures from Bangladeshi children with septicaemia: an evaluation of conventional, lysis-direct plating and lysis-centrifugation methods.
Trans. R. Soc. Trop. Med. Hyg.
86:554-556[CrossRef][Medline].
|
| 11.
|
Saha, S. K., and S. Saha.
1994.
Antibiotic resistance of Salmonella typhi in Bangladesh.
J. Antimicrob. Chemother.
33:190-191[Free Full Text].
|
| 12.
|
Saha, S. K.,
S. Setarunnahar,
M. Ruhulamin,
M. Hanif, and I. Maksuda.
1997.
Decreasing trend of multiresistant Salmonella typhi in Bangladesh.
J. Antimicrob. Chemother.
39:554-556[Free Full Text].
|
| 13.
|
Saha, S. K.,
S. Y. Talukder,
M. Islam, and S. Saha.
1999.
A highly cefriaxone-resistant Salmonella typhi in Bangladesh.
Pediatr. Infect. Dis. J.
18:387[CrossRef][Medline].
|
| 14.
|
Trenholme, C. D.,
R. D. Kaplan,
P. Karakusis, et al.
1989.
Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates.
J. Clin. Microbiol.
27:1342-1345[Abstract/Free Full Text].
|
| 15.
|
Weinstein, W. P.
1996.
Current blood culture methods and systems: clinical concepts, technology, and interpretation of results.
Clin. Infect. Dis.
23:40-46[Medline].
|
Journal of Clinical Microbiology, October 2001, p. 3583-3585, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3583-3585.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
de Cueto, M., Ceballos, E., Martinez-Martinez, L., Perea, E. J., Pascual, A.
(2004). Use of Positive Blood Cultures for Direct Identification and Susceptibility Testing with the Vitek 2 System. J. Clin. Microbiol.
42: 3734-3738
[Abstract]
[Full Text]